312 related articles for article (PubMed ID: 28498503)
21. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
Zhang W; Wu FX; Wang Q; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
[TBL] [Abstract][Full Text] [Related]
22. Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation.
Battista RA; Resnati M; Facchi C; Ruggieri E; Cremasco F; Paradiso F; Orfanelli U; Giordano L; Bussi M; Cenci S; Milan E
PLoS One; 2018; 13(8):e0201621. PubMed ID: 30067838
[TBL] [Abstract][Full Text] [Related]
23. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
24. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
26. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
[TBL] [Abstract][Full Text] [Related]
28. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
29. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
30. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
31. TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways.
Zhang L; Dittmer MR; Blackwell K; Workman LM; Hostager B; Habelhah H
Cell Signal; 2015 Feb; 27(2):306-14. PubMed ID: 25446254
[TBL] [Abstract][Full Text] [Related]
32. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
33. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
Gong S; Chen Y; Meng F; Zhang Y; Wu H; Li C; Zhang G
FASEB J; 2019 Apr; 33(4):5350-5365. PubMed ID: 30768358
[TBL] [Abstract][Full Text] [Related]
34. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
35. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
37. p62 aggregates mediated Caspase 8 activation is responsible for progression of ovarian cancer.
Yan XY; Zhong XR; Yu SH; Zhang LC; Liu YN; Zhang Y; Sun LK; Su J
J Cell Mol Med; 2019 Jun; 23(6):4030-4042. PubMed ID: 30941888
[TBL] [Abstract][Full Text] [Related]
38. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
Zhang TM
Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
[TBL] [Abstract][Full Text] [Related]
39. Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
Alsamman K; El-Masry OS
Oncol Rep; 2018 Oct; 40(4):2157-2162. PubMed ID: 30106434
[TBL] [Abstract][Full Text] [Related]
40. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
